1,099.40 -1.60(-0.15%)
Open Price (₹)
Prev. Close (₹)
Volume (No’s)
Market Cap (₹)
Low Price (₹)
High Price (₹)
OI(₹)
Market Cap(₹Cr.)
P/E (TTM)
Book value (₹)
Div Yield (%)
EPS (TTM)
Face Value (₹)
Key Level
Resistance 1
Resistance 2
Support 1
Support 2
Moving Average
30 Days
50 Days
100 Days
200 Days
This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.
If I had made LUMPSUM investment of ₹ Returns(%)
in 12 36 60 Months Ago
My investment would be worth₹ with a Loss of
Aurobindo Pharma Limited (APL), one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in December 1986 as a private limited company. Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it. APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations. The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindo's products. APL is running with 29 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities. Aurobindo Pharma has identified international operations also catering to over 150 countries. The Company has accelerated the DMF/ANDA filings programme in its efforts to build a broad product portfolio for the regulated markets. Cumulatively, the Company has filed a total of 337 DMFs (Drug Master Files), of which 110 are with US FDA, and 133 in Europe including ...